Broadly Neutralizing Antibodies

A new HIV vaccine candidate developed by the Duke Human Vaccine Institute showed promise in a phase 1 trial, generating broadly neutralizing antibodies and strong immune responses in 20 healthy participants.

A new HIV vaccine candidate developed by the Duke Human Vaccine Institute showed promise in a phase 1 trial, generating broadly neutralizing antibodies and strong immune responses in 20 healthy participants.